How Much Does Peptide Therapy Cost in 2026? What Drives the Price

How much does peptide therapy cost in 2026?

Peptide therapy cost depends on the prescription, the pharmacy, and monitoring. At Revive, the individual therapies covered in this guide are $149 to $359 per 4 weeks if prescribed, and memberships are $299 to $999 per 4 weeks. Novo Nordisk and Lilly list self-pay prices of about $199 to $449 per month for most doses of the two FDA-approved GLP-1 injections, Wegovy and Zepbound, rising to $699 for the highest Zepbound doses if a refill falls outside the 45-day window. Most other therapies discussed here have no FDA-approved counterpart to price against. Compounded products are not FDA-approved.

Every price below is per 4 weeks or per month as labeled, and subject to change and eligibility. The manufacturer figures come from each drugmaker’s own self-pay pages.

What you are actually paying for: the five cost drivers

A per-4-week price bundles clinical work, pharmacy work, and logistics that a mail-order listing skips.

1. Licensed-provider evaluation and a valid prescription

Under section 503A of the Food, Drug, and Cosmetic Act, a compounded drug is made for an identified patient on a valid prescription. A clinician licensed in your state reviews your history and decides whether treatment is appropriate.

2. A state-licensed 503A compounding pharmacy

FDA is direct: “Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.” Pharmacies compounding under section 503A are state-licensed and not subject to federal CGMP manufacturing requirements. Poor practices can cause contamination or a drug with too much or too little active ingredient, so sterile technique, testing, and trained staff cost money.

3. Lab work

Many therapies are appropriate only after blood work confirms a diagnosis or baseline, and follow-up labs check your response. At Revive, panels are tied to membership level, not the product price, and the entry-level tier does not include one.

4. Ongoing monitoring and dose adjustments

FDA has received “multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors associated with compounded injectable semaglutide products.” Follow-up and a titration plan separate supervised treatment from a box in the mail.

5. Dispensing and shipping

The pharmacy must be licensed to ship into your state and keep temperature-sensitive products stable in transit. Revive ships from a licensed pharmacy in unbranded packaging, with free shipping. Ask any clinic whether shipping or processing fees are added, since practices differ.

Cost driver	What it covers
Provider evaluation and prescription	History review, eligibility decision, individual prescription
503A compounding pharmacy	Sterile compounding, potency and contamination controls
Lab work	Baseline and follow-up panels, reviewed by a clinician
Monitoring and dose adjustment	Follow-up visits, titration, side-effect management
Dispensing and shipping	Pharmacist oversight, temperature-controlled packaging, licensed shipping

Revive therapy prices per 4 weeks

These are the listed prices on Revive’s product pages, per 4 weeks, only if a licensed provider prescribes the therapy, and subject to change and eligibility. This table is the authority for the $149 to $359 range quoted above. Revive’s wider menu lists other items at their own prices, including the Truck Driver Stack at $579 per 4 weeks and the NAD+ Face Cream at $159, a cosmetic rather than a prescription therapy. Not every item is a peptide: sermorelin, glutathione, and PT-141 are; testosterone, HRT, and hCG are hormones; enclomiphene is a selective estrogen receptor modulator; NAD+ is a coenzyme. Every compounded product below is not FDA-approved.

Therapy	Price per 4 weeks (if prescribed)	Regulatory note
HRT	$149	FDA-approved progesterone and estradiol products exist. Where compounded, not FDA-approved or evaluated by FDA for safety, quality, or efficacy (see bioidentical hormones).
TRT (testosterone)	$159	FDA-approved testosterone products exist (Schedule III controlled substances), approved solely for low testosterone with an associated medical condition, not for age-related low testosterone. Where compounded, not FDA-approved.
Enclomiphene	$159	Compounded, not FDA-approved. 503A Category 1 (under FDA evaluation).
NAD+ Nasal Spray	$159	Compounded, not FDA-approved. NAD is 503A Category 1.
Lipotropic + B12	$159	Compounded, not FDA-approved.
Sermorelin	$179	Compounded, not FDA-approved. No sermorelin product is currently marketed with FDA approval; Geref was discontinued.
NAD+	$179	Compounded, not FDA-approved. 503A Category 1.
Glutathione	$179	Compounded, not FDA-approved. 503A Category 1.
PT-141 (bremelanotide)	$199	Compounded, not FDA-approved. The only approved bremelanotide is Vyleesi, for premenopausal women with HSDD; use in men is off-label.
Tirzepatide	$279	Compounded, not FDA-approved (Mounjaro and Zepbound are the approved products). Prescribed only where a provider documents an individual clinical need.
HCG	$359	FDA-approved hCG products exist for certain fertility and hormonal conditions. FDA states hCG is not approved for weight loss. Where compounded, not FDA-approved.

Membership tiers

Revive’s pricing page lists three levels, each billed per 4 weeks, and states: “Therapies, screenings, and protocols are provided only when clinically appropriate based on your physician evaluation.”

Tier	Price per 4 weeks	Products included	Blood panels	Also included
Foundation	$299	1	Not included	Initial physician evaluation and health review, custom workout plan in the Revive Longevity app, secure patient portal access
Core Optimization	$599	Up to 3	2 per year	Everything in Foundation, plus an individualized diet plan
Private Optimization	$999	Up to 4	4 per year	Everything in Core, plus a monthly live Q&A call with a doctor or industry expert

What the FDA-approved products cost, for reference

Cost is not a clinical reason to use a compounded drug in place of an FDA-approved one. FDA’s position is that compounded drugs should be used only by patients whose medical needs cannot be met by an FDA-approved drug.

NovoCare Pharmacy lists Wegovy pens at a flat monthly price with no refill-window requirement. Lilly publishes regular self-pay prices per dose for the Zepbound single-patient-use KwikPen, plus a $449 purchase offer that new and existing patients receive automatically on a first purchase of the 7.5 mg through 15 mg pens and keep while refills stay inside a 45-day window, so $449 is the working self-pay price at those doses. Novo Nordisk’s $199 rate runs through December 31, 2026. An FDA-approved option can also cost less than a compounded one: Wegovy tablets start at $149 per month, below Revive’s $279 per 4 weeks for compounded tirzepatide, one more reason price alone is not a clinical rationale.

Product	FDA status	Manufacturer self-pay price (per month)	Conditions
Wegovy pen (semaglutide)	FDA-approved	$349 for 0.25 mg, 0.5 mg, 1 mg, 1.7 mg or 2.4 mg; $399 for Wegovy HD 7.2 mg; $199 for the 0.25 mg and 0.5 mg starter doses, for 2 monthly fills, for patients new to the offer	NovoCare Pharmacy self-pay; one month is 1 box of 4 pens; eligibility and restrictions apply
Wegovy tablets (semaglutide)	FDA-approved	$149 per month (1.5 mg), $199 (4 mg), $299 (9 mg and 25 mg)	NovoCare Pharmacy self-pay; one month is 1 bottle of 30 tablets; eligibility and restrictions apply
Zepbound single-patient-use KwikPen (tirzepatide)	FDA-approved	$299 (2.5 mg), $399 (5 mg), and $449 for 7.5 mg, 10 mg, 12.5 mg and 15 mg under Lilly’s purchase offer, which new and existing patients receive automatically on a first purchase and keep while each refill is bought within 45 days of the previous delivery. Without that offer: $499 (7.5 mg) and $699 (10 mg, 12.5 mg and 15 mg) for a 1-month supply (28 days, 1 pen).	Lilly’s published self-pay prices; the purchase offer has no stated end date and Lilly may terminate, rescind, revoke or amend it at any time. Lilly’s savings card is a separate program, limited to patients with commercial drug insurance and ending December 31, 2026.

Two comparisons have no benchmark. Bremelanotide is FDA-approved only as Vyleesi, for premenopausal women with acquired, generalized hypoactive sexual desire disorder, so compounded PT-141 used in men has no approved counterpart. And sermorelin has no currently marketed FDA-approved product at all: Drugs@FDA lists both strengths of Geref (sermorelin acetate, EMD Serono, approved 09/26/1997) as Discontinued, not withdrawn for safety or effectiveness reasons.

Why cheap “research peptides” are not a like-for-like comparison

Vials sold online for a fraction of a clinic’s price are usually labeled “research use only.” In a June 2026 warning letter to one such seller, FDA wrote that despite “RESEARCH USE ONLY” labeling, the seller’s website “establishes that your products are intended to be drugs for human use,” which makes them unapproved new drugs. FDA added that injectable products “bypass some of the body’s key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions.”

FDA has also flagged products marketed as semaglutide that actually contain semaglutide sodium or semaglutide acetate, which “are different active ingredients than are used in the approved drugs.” As of May 31, 2026, FDA had received 990 adverse event reports involving compounded semaglutide and more than 730 involving compounded tirzepatide. These are reports, not proof of causation, but dosing errors and product quality are real risks without supervision. A research vial also carries none of the five cost drivers above.

How regulatory status shapes what a clinic can offer

Under section 503A, a pharmacy may use only bulk substances that have a USP or NF monograph, are components of FDA-approved drugs, or appear on FDA’s 503A bulks list. Nominated substances outside those groups sit in interim categories: Category 1 may be used during FDA’s evaluation, Category 2 is flagged for significant safety risks, and Category 3 lacked enough information.

• Enclomiphene, glutathione, and NAD+: all three sit in 503A Category 1 under FDA’s interim policy for nominated bulk substances, on FDA’s list of bulk drug substances nominated for use in compounding under section 503A, last updated May 14, 2026: compoundable during evaluation, but not FDA-approved.
• Tirzepatide and semaglutide: FDA determined the tirzepatide shortage resolved in 2024 and the semaglutide shortage resolved on February 21, 2025. Once a drug is commercially available, 503A pharmacies may not regularly compound “essentially copies” of it; a compounded version requires a documented significant difference for an identified patient. Compounded GLP-1s are not routinely available (see compounded tirzepatide in 2026).
• BPC-157, TB-500, CJC-1295, ipamorelin, MOTS-c, and AOD-9604: FDA has identified potential significant safety risks for each of these substances, including immunogenicity risk and limited or absent human safety data. FDA’s safety-risk page (content current as of April 22, 2026) lists all six among bulk substances previously in category 2 whose nominations were withdrawn by the nominators, with FDA’s safety notes retained. Ipamorelin acetate also appears in FDA’s active category 2 table because it remains in category 2 under the 503B interim policy (added September 29, 2023), where FDA cites serious adverse events including death when ipamorelin was administered intravenously. None of the six appears on FDA’s 503A bulks list or in 503A category 1, so a 503A pharmacy cannot compound them. Revive does not offer these peptides, and this mention is educational only (see the FDA July 2026 peptide review).
• Testosterone and hCG: both have FDA-approved products. DEA’s list of controlled substances places testosterone in Schedule III (see is testosterone a controlled substance?), and FDA’s February 2025 class labeling approves it solely for low testosterone with an associated medical condition, so a real TRT evaluation involves diagnostic labs (see our TRT cost guide). On hCG, FDA is explicit that it is not approved for weight loss, and the prescription label notes there is no substantial evidence that it increases weight loss beyond that resulting from caloric restriction. FDA also warns consumers away from over-the-counter “HCG diet” products.

Insurance, membership models, and fees to watch for

Revive’s pricing page states: “We do not accept insurance.” Whether another clinic bills insurance, and whether your plan covers a compounded therapy, is worth confirming directly (see is TRT covered by insurance?). The page also states that members can “cancel or pause anytime” and that “not all applicants qualify.” Anywhere you shop, ask in writing what the price excludes: follow-up visits, labs, refills, shipping, and cancellation terms.

Questions to ask any clinic before you pay

These apply to every clinic, including Revive.

1. Is the prescriber licensed in my state, and does every therapy require a prescription after an evaluation?
2. Which pharmacy fills it, is it licensed by a state board of pharmacy, and is a pharmacist reachable by phone?
3. Is the clinic certified by an independent third party such as LegitScript, and is that certification current?
4. Is the price per 4 weeks, with inclusions (evaluation, product, labs, follow-up, shipping) spelled out, and does the clinic say which products are compounded and not FDA-approved?

How Revive approaches peptide therapy pricing

Revive Longevity is a LegitScript-certified clinic. The process starts with a short online assessment that a provider licensed in your state reviews before writing any prescription. If a therapy is prescribed, a state-licensed 503A pharmacy dispenses it and ships it in unbranded packaging with free shipping. Compounded medications are not FDA-approved, and FDA has not evaluated them for safety, quality, or efficacy.

Prices are published per 4 weeks on each product page and on the pricing page, subject to change and eligibility. Not all applicants qualify, and an evaluation does not mean a prescription will be written (see how Revive works).

Frequently asked questions

How much does peptide therapy cost per month?

At Revive, the individual prescription therapies covered in this guide are listed at $149 to $359 per 4 weeks if prescribed, and memberships run $299, $599, or $999 per 4 weeks. Prices are subject to change and eligibility, and a licensed provider decides whether any therapy is appropriate. Revive does not accept insurance.

Can compounded tirzepatide be used instead of Zepbound?

Not as a routine substitute. FDA determined the tirzepatide shortage resolved in 2024, so compounded tirzepatide, which is not FDA-approved, may be prescribed only where a licensed provider documents an individual clinical need. Revive lists it at $279 per 4 weeks if prescribed. For reference, Lilly’s self-pay price for a 1-month supply of the Zepbound KwikPen is $299 (2.5 mg), $399 (5 mg), and $449 for 7.5 mg through 15 mg under a purchase offer that applies automatically for new and existing patients and continues while refills stay inside a 45-day window; the regular $499 (7.5 mg) and $699 (10 mg through 15 mg) apply only if that window lapses. Cost is not a clinical reason to use a compounded drug in place of an FDA-approved one.

Why are “research use only” peptides so much cheaper?

Because they skip everything a prescription price includes: provider evaluation, a valid prescription, a state-licensed pharmacy, pharmacist oversight, labs, and follow-up. FDA has stated in warning letters that a “research use only” label does not change that these products are unapproved drugs intended for human use.

What does a Revive membership include?

Per the pricing page: Foundation ($299 per 4 weeks) includes an initial physician evaluation and health review, 1 product, a custom workout plan in the Revive Longevity app, and secure patient portal access; blood panels are not included at this tier. Core Optimization ($599) adds up to 3 products, 2 blood panels per year, and an individualized diet plan. Private Optimization ($999) adds up to 4 products, 4 blood panels per year, and a monthly live Q and A call with a doctor or industry expert. Not all applicants qualify.

Are compounded peptides FDA-approved?

No. Compounded medications are not FDA-approved, and FDA does not verify their safety, effectiveness, or quality before they are marketed. Some have FDA-approved counterparts (tirzepatide as Mounjaro and Zepbound, bremelanotide as Vyleesi, which is indicated only for premenopausal women with HSDD); others, such as sermorelin, have no currently marketed approved product at all.

Do I need lab work, and is it included in the price?

Many therapies call for baseline and follow-up blood work, and testosterone requires a diagnosis, not just symptoms. At Revive, panels are membership inclusions (not included at Foundation, 2 per year on Core Optimization, 4 per year on Private Optimization), not part of the product prices. Ask any clinic how many are included.